[Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure]

What Was Tested

The paper reports a study of Pancreatic Polypeptide, published as a controlled clinical trial.

The study aimed to assess the influence of long-term rhu-EPO treatment on secretion of pancreatic polypeptide (PP) and gastrin.

Why It Was Studied

A total of 27 haemodialysed patients and nine healthy subjects were examined.

In all subjects plasma levels of PP and gastrin were estimated before and after administration of a test meal.

Who Took Part

According to the abstract, 27 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults.

Nine patients with uraemic anaemia were treated with rhu-EPO for 12 months (EPO group), while another nine patients did not receive rhu-EPO (non-EPO group), but were monitored biochemically and clinically as patients of the EPO group.

How the Study Was Run

The methods mention a period of 12 months.

What Was Measured

In all subjects plasma levels of PP and gastrin were estimated before and after administration of a test meal.

Patients of the EPO and non-EPO group were examined before and after 6 and 12 months of rhu-EPO therapy (EPO group) or clinical monitoring (non-EPO group) respectively, while only one test was performed in patients of the HD group and healthy subjects.

The subject headings attached to it are Erythropoietin, Gastrins, Kidney Failure, Chronic, Pancreatic Polypeptide, Recombinant Proteins and Renal Dialysis.

What This Means in Plain Language

This is a controlled clinical trial of Pancreatic Polypeptide in 27 patients over 12 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1995 (Przeglad lekarski), a journal based in Poland.

More context: the Pancreatic Polypeptide compound page, all human trials.